Skip to content
Disclosery

Remedium Capital Partners, LLC

Follow

13F filer, CIK 2104501, WEST PALM BEACH, FL

Remedium Capital Partners, LLC reported $281,150,119 across 6 holdings for the quarter ended 2026-03-31, in a 13F-HR/A filed 2026-05-19.

Filed (acceptance time not in the bulk data set), ingested 13F-HR/A 0002104501-26-000010

Period
2026-03-31
Reported value
$281M
Holdings
6
Top 10 weight
100%
New
0
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
DMRAadded+1,925,000$49.9M
ORKAadded+13,247$650K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

None.

Holdings, Q1 2026

Share positions as resolved from 13F-HR/A 0002104501-26-000010, largest first. % of portfolio is the value over $281,150,119, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 1,552,414 shares; 2026Q1: 1,565,661 shares 1,565,661$76.8M27.31%+13,247Timeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 1,456,231 shares; 2026Q1: 1,456,231 shares 1,456,231$73.5M26.13%0Timeline
DMRADAMORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 120,473 shares; 2026Q1: 2,045,473 shares 2,045,473$53M18.84%+1,925,000Timeline
APGEAPOGEE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 583,591 shares; 2026Q1: 583,591 shares 583,591$49.1M17.47%0Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 1,577,750 shares; 2026Q1: 1,577,750 shares 1,577,750$22.2M7.88%0Timeline
CRESCENT BIOPHARMA INC.CRESCENT BIOPHARMA INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 361,250 shares; 2026Q1: 361,250 shares 361,250$6.64M2.36%0

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0002104501-26-000008 superseded2026-05-13acceptance time not in the bulk data set
13F-HR/A 0002104501-26-000010 baserestatement2026-05-19acceptance time not in the bulk data set